Lefax

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lefax

Property Description
Active ingredient Simethicone
Form Oral suspension (drops/liquid), Chewable tablets, Soft capsules
Pharmacological class Gastrointestinal agent (Antiflatulent)
Common use Relief of gas, bloating, and feeling of fullness
Origin Synthetic (Silicone compound)

What is Lefax and What Class Does it Belong To?

Lefax is a recognized trade name for an over-the-counter medicine designed for the relief of gastrointestinal discomfort caused by excess gas. Its single active ingredient, Simethicone, belongs to the miscellaneous GI agents class, specifically recognized as an antiflatulent. This monopreparation is primarily intended to manage the pressure and pain that arise from gas trapped within the digestive system. Simethicone's non-systemic mode of action is a distinguishing feature; the substance is not absorbed into the bloodstream but performs its function entirely within the stomach and intestines.

Simethicone: Origin, Composition, and Available Forms

The active ingredient Simethicone is a stable, synthetic silicone compound—specifically a mixture of polydimethylsiloxanes and silica gel. The brand is often known for its oral suspension form, commonly referred to as drops or liquid, which is specifically formulated for infants and younger children, differentiating it from adult-focused preparations. To suit various patient needs, Lefax is also manufactured in chewable tablets and soft capsules for oral administration. Simethicone acts locally in the gastrointestinal tract to disrupt the foam layer, which results in a minimal risk of systemic side effects.

How Does Lefax Provide General Relief?

Lefax provides general relief by physically assisting the body in the removal of gas that is trapped within the gastrointestinal tract, which can occur after consuming certain foods. It alleviates symptoms such as uncomfortable bloating, abdominal fullness, and pressure from meteorism. The compound acts as a surfactant to reduce the high surface tension of the numerous small, persistent foam bubbles that impede gas passage. By causing these bubbles to coalesce into larger, free gas pockets, the medication facilitates the easier and more natural expulsion of the gas, resolving the physical source of the patient’s discomfort. Simethicone's defoaming action is a functional approach for symptomatic relief of excess gas.

Regulatory References

  1. Simethicone: MedlinePlus Drug Information

What side effects are possible with Lefax?

Possible Side Effects and Safety Information

The official safety profile for the active ingredient, Simethicone, is documented by government regulatory authorities and primarily reflects its non-systemic mode of action. Adverse reactions are classified according to regulatory frequency tiers, predominantly involving the gastrointestinal tract and immune system responses.

Official Frequency Classification of Adverse Reactions

Adverse effects are mostly reported as rare or uncommon, based on official labeling. The following classifications are used to describe the frequency with which these events are reported:

Classification Examples of Reactions
Uncommon (0.1% to 1%) Constipation, Nausea
Rare (0.01% to 0.1%) Tongue oedema, Face oedema, Pruritus, Rash, Respiratory difficulty
Other Diarrhea or Loose stools

Serious Safety Considerations

A severe allergic reaction, including anaphylaxis, is officially listed in regulatory safety documentation as a rare but serious possible adverse event. These hypersensitivity reactions, which are classified within the Immune System Disorders category, are the most clinically significant safety concern documented for the medicine.

Population-Specific Safety and Restrictions

Due to Simethicone’s lack of systemic absorption from the digestive tract, adverse effects on pregnancy and lactation are generally not anticipated. The official safety constraints on the medicine are centered on high-level risks:

  • Contraindication: Use is formally prohibited for individuals with documented hypersensitivity to the active substance or any of the product's excipients.
  • Drug Interaction Note: Regulatory documents note that co-administration may impair the absorption of Levothyroxine, a safety consideration explicitly highlighted, particularly when treating infants with thyroid conditions.

This structure ensures the safety profile focuses on the local action of the ingredient and officially documented hypersensitivity risks.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Lefax (Simethicone) is uniquely structured by the active ingredient’s pharmacology, which dictates the documented risks and emergency actions.

Feature Official Regulatory Statement
Documented Overdose Presentations No specific symptoms or clinical signs of overdose are formally known or documented in official regulatory labeling.
Physiological Systems Affected None. The substance is documented as not being absorbed systemically; it remains in the gastrointestinal tract and is excreted unchanged.
Dose-Related Factors Serious clinical outcomes are consistently deemed unlikely following overdosage due to the non-systemic absorption profile.
When Immediate Medical Help Is Required When a suspected overdose has occurred, urgent medical help is required as per official prescribing information.

Emergency Actions and Overdose Management

Regulatory labeling mandates that immediate medical attention must be sought or a Poison Control Center must be contacted immediately in the event of a suspected overdose. This action is the primary safeguard required by regulatory authorities.

Official overdose statements:

  • No specific antidote for Simethicone is known or documented in regulatory prescribing information.
  • Management is generally limited to supportive and symptomatic treatment, as required.

Connection to the overall overdose profile

Regulatory documents define the overdose profile based on the active ingredient’s non-systemic absorption, leading to the official conclusion that no overdose symptoms are known. Despite the low risk, regulatory information requires the action of seeking immediate medical help as the primary safety mandate when an overdose is suspected.

Therapeutic Uses of Lefax

What Lefax Treats: Main Uses and Benefits

The core therapeutic domain of Lefax is associated with symptomatic relief in situations involving physical discomfort and pressure from trapped gas. The medication is utilized to help manage the symptomatic burden of gas.

The primary therapeutic benefit is commonly applied to help with conditions characterized by episodic or fluctuating manifestations, such as flatulence and functional gastric bloating. It is used to address symptom clusters that create noticeable physiological strain, primarily abdominal distension, a feeling of fullness, and resulting painful pressure.

Lefax is also applied in clinical settings that involve acute or unstable symptom patterns; it is relevant when supportive symptom management is appropriate for postoperative gas pains following surgery. It may also assist with the reduction of gas shadows prior to diagnostic procedures like gastroscopy or radiography.

Quick Fact: Symptomatic Management of Pressure-Related Symptoms

Relevant in conditions characterized by: episodic gas discomfort and bloating
Key Benefit: Contributes to easing the overall symptom load
Patient Focus: Applicable across all relevant age groups

Regulatory References

  1. NIH MedlinePlus Drug Information on Simethicone

Eligibility and Restrictions for Use

Lefax, whose primary active ingredient is Simethicone, is an over-the-counter medicine used to treat symptoms of excessive gas in the gastrointestinal tract, such as flatulence, bloating, and abdominal pressure. Its mechanism is entirely physical—it is not absorbed into the bloodstream, limiting its systemic effects.

Simethicone-only formulations of Lefax are generally considered safe for use in most populations when taken according to the package instructions. This includes:

  • Adults and Adolescents
  • Children and Infants: Specific dosage forms (like drops) are available and considered safe, though efficacy for conditions like infantile colic remains debated in clinical studies.
  • Pregnancy and Breastfeeding: Due to the lack of systemic absorption, simethicone is considered compatible with use during pregnancy and while breastfeeding.

Contraindications and Cautions

Lefax should not be used by individuals who have a known hypersensitivity or allergy to simethicone or any of the product's other ingredients.

Patients should consult a healthcare professional before use if symptoms are severe, persistent, or accompanied by other concerning signs like fever, vomiting, or blood in the stool. Certain complex formulations of Lefax, such as those that combine simethicone with other substances like digestive enzymes or antibiotics (which may be sold under similar brand names), may have different contraindications concerning age or specific medical conditions like acute pancreatitis or certain kidney diseases.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Lefax (Simethicone) has a highly specific interaction profile governed by its lack of systemic absorption. Regulatory authorities document a notable absence of metabolic (pharmacokinetic) or pharmacodynamic interactions because the active substance does not enter the bloodstream to interfere with liver enzymes or systemic drug receptors. Consequently, Simethicone is not classified as a CYP enzyme inhibitor or inducer.

Documented Physical Interactions

The documented interactions relate primarily to a physical effect within the gastrointestinal tract. Co-administration of Lefax with certain oral medications may result in reduced absorption of the other drug, potentially lowering its intended systemic exposure. The most commonly cited interaction involves oral thyroid hormone preparations, such as Levothyroxine.

Administration Requirements

Due to the risk of physically reducing the absorption of thyroid hormones, the official interaction guidance requires the separation of administration timing for these medicines. This constraint is a localized physical interaction rule, not a systemic metabolic restriction. No formal contraindications (prohibited combinations) are listed based on interaction risk. Regulatory resources also note a localized interference with oral lactase treatments in infants.

Mechanism of Action

Lefax operates via a unique physical-chemical mechanism that is entirely non-systemic; the active ingredient, Simethicone, does not absorb into the bloodstream or interact with any classical biological targets, such as receptors, enzymes, or neural pathways.

Physicochemical Defoaming Action

Simethicone functions as a surfactant that directly targets the gas-liquid interface of foam bubbles in the stomach and intestines. Its mechanism involves a dramatic reduction of the surface tension of the bubble walls, which causes numerous small, trapped foam bubbles to immediately coalesce into larger, contiguous gas pockets.

Systemic Consequence of Local Mechanical Clearance

This shift from trapped foam to large, free gas pockets modifies the state of the GI contents, permitting gas expulsion via physiological processes, such as belching (eructation) or flatulence. The overall resulting physiological effect is the reduction of abdominal physical distention, effected by directly altering the mechanical state of pressure within the GI lumen.

Mechanistic Scope and Limitations

The drug's mechanism is defined by local mechanical action, which aids gas clearance, but does not inhibit gas production. The mechanism is strictly dependent on the existence of foam-like trapped gas for its action.

Dosage and Administration Information

How Lefax is Used: Official Administration Guidelines

The principles for using Simethicone—the single active ingredient in Lefax—are fundamentally tied to its oral administration and non-systemic function within the gastrointestinal tract. The medication is available in dosage forms including soft capsules, chewable tablets, and an oral suspension (drops).


Dosing Regimens and Frequency

Dosing is typically intermittent and based on symptomatic need, with the primary schedule being up to four times daily (QID). For adults, the usual single dose ranges from 40 mg to 360 mg. This administration pattern involves a total dose not exceeding 500 mg within a 24-hour period. Dosing is often administered after meals and at bedtime to align with periods when gas discomfort frequently occurs.

Administration and Preparation

Proper use of the medication depends on the specific dosage form. The oral suspension must be shaken well immediately before measurement, and the dose must be accurately measured using a calibrated dropper or device. For infant use, the drops can be mixed with water, formula, or other suitable liquid carriers. Chewable tablets, conversely, require the tablet to be chewed thoroughly before being swallowed.

Usage Condition Official Instruction
Pediatric Dosing (Infants < 2 years) Typical dose is 20 mg, max 240 mg/24 hours.
Pediatric Dosing (Children 2–12 years) Typical dose is 40 mg, max 480 mg/24 hours.
Special Procedural Constraint When co-administering with oral thyroid hormone medicines, Simethicone must be taken at least four hours before or after the thyroid medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Simethicone for Gas and Bloating

Research has explored the use of simethicone (the active ingredient in Lefax) in relation to symptoms caused by excess gas, such as bloating, fullness, and flatulence. The compound’s effect relates to its physical action as an antifoaming agent within the gastrointestinal tract.

Studies investigated the observed changes in patient-reported symptoms, including:

  • Adult Symptoms: Some double-blind, randomized trials comparing simethicone to placebo for symptoms like gas, heartburn, and bloating have assessed the change in symptom severity and frequency over periods such as 10 days.
  • Infant Colic: Clinical data regarding simethicone's effect on infantile colic symptoms remain inconclusive. Several randomized controlled trials have reported no statistically significant difference in reducing crying time compared with a placebo, while other studies have been mixed.

Safety and Tolerability

The compound’s tolerability and safety parameters were assessed across numerous clinical studies, with simethicone noted as not being absorbed into the body. Data on tolerability were derived from the clinical trials, which tracked participant withdrawal rates due to adverse events.

  • Comparative Data: Head-to-head trials have compared simethicone to other agents for symptoms like functional bloating in adults. Such studies reported different frequencies of adverse events between simethicone groups and comparison groups.

Frequently Asked Questions (FAQ)

Common questions about Lefax (FAQ)

Q: What is Lefax used for?

A: Lefax is generally used to help relieve symptoms associated with excessive gas accumulation in the gastrointestinal tract, such as flatulence, bloating, and a feeling of fullness. Its purpose is typically to assist in the dispersal of gas bubbles.

Q: How does the ingredient in Lefax work?

A: The active ingredient, simethicone, is a defoaming agent. It works on the surface tension of gas bubbles in the stomach and intestines, causing them to break down. This process may help make it easier for gas to be passed or absorbed by the body.

Q: Can I use Lefax for baby colic?

A: Some formulations of the active ingredient may be used in infants, and a doctor should be consulted before giving any product to a baby for symptoms like colic. The choice of specific product and administration should always be guided by a healthcare professional.

Q: When should I not take Lefax?

A: Individuals who have known allergies to the active ingredient (simethicone) or any other components of the product should not use it. If you suspect an intestinal obstruction or have persistent, severe abdominal pain, it is important to seek medical advice immediately.

How should Lefax be stored and disposed of?

Storage and Container Requirements

Lefax (Simethicone) must be stored under specific conditions to maintain its labeled quality. The product should be stored at a temperature not exceeding 25 C and must be protected from light and moisture. Regulatory documents explicitly state that the medicine must not be refrigerated or frozen. The product should remain in its original container, and the cap must be kept tightly closed.

Stability and Child Safety

All medicine must be discarded after the expiration date. For the Lefax oral suspension/drops, the opened bottle has an in-use stability period and must be used within 13 weeks of the first opening. As a mandatory safety requirement, Lefax must be kept out of the sight and reach of children.

Official Disposal Rules

Unused or expired Lefax must not be disposed of in wastewater or household waste. To ensure proper disposal and environmental protection, users are instructed to ask a pharmacist for guidance on how to discard the medicine when it is no longer needed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lefax found in:

A-Z Index: